Literature DB >> 2370681

Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees.

P L Nara1, L Smit, N Dunlop, W Hatch, M Merges, D Waters, J Kelliher, R C Gallo, P J Fischinger, J Goudsmit.   

Abstract

Emergence in two chimpanzees of human immunodeficiency virus type 1 (HIV-1) IIIB variants resistant to neutralization by the preexisting antibody is described. Viruses isolated from the HIV-1 IIIB gp120-vaccinated and -challenged animal were more resistant to neutralization by the chimpanzee's own serum than viruses isolated from the naive infected animal, indicating immune pressure as the selective mechanism. However, all reisolated viruses were 16- to 256-fold more neutralization resistant than the inoculum virus to antibodies binding to the third variable domain (V3) of the HIV-1 external envelope. Early chimpanzee serum samples that neutralized the inoculum strain but not the reisolated viruses were found to bind an HIV-1 IIIB common nonapeptide (IQRGPGRAF) derived from the gp120 isolate-specific V3 domain shown to induce isolate-specific neutralization in other animals. Amplification of the V3 coding sequence by polymerase chain reaction and subsequent sequence analysis of the neutralization-resistant variants obtained from in vivo-infected animals indicated that early resistance to neutralization by an HIV-1 IIIB monoclonal antibody (0.5 beta) was conferred by changes outside the direct binding site for the selective neutralizing antibody. The reisolated neutralization-resistant isolates consisted of the lower-replication-competent virus subpopulations of the HIV-1 IIIB stock, as confirmed by biological and sequence analyses. In vitro passage of the HIV-1 IIIB stock through chimpanzee and human peripheral blood mononuclear cell cultures void of HIV-specific antibody resulted in homogenic amplification of the more-replication-competent subpopulation preexisting in the original viral stock, suggesting a role for the immune system in suppressing the more-replication-competent viruses.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2370681      PMCID: PMC249673     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Infection of chimpanzees with lymphadenopathy-associated virus.

Authors:  D P Francis; P M Feorino; J R Broderson; H M McClure; J P Getchell; C R McGrath; B Swenson; J S McDougal; E L Palmer; A K Harrison
Journal:  Lancet       Date:  1984-12-01       Impact factor: 79.321

2.  Rapid emergence of novel antigenic and genetic variants of equine infectious anemia virus during persistent infection.

Authors:  O Salinovich; S L Payne; R C Montelaro; K A Hussain; C J Issel; K L Schnorr
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

3.  Persistent infection of chimpanzees with human T-lymphotropic virus type III/lymphadenopathy-associated virus: a potential model for acquired immunodeficiency syndrome.

Authors:  P N Fultz; H M McClure; R B Swenson; C R McGrath; A Brodie; J P Getchell; F C Jensen; D C Anderson; J R Broderson; D P Francis
Journal:  J Virol       Date:  1986-04       Impact factor: 5.103

4.  Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS.

Authors:  B H Hahn; G M Shaw; M E Taylor; R R Redfield; P D Markham; S Z Salahuddin; F Wong-Staal; R C Gallo; E S Parks; W P Parks
Journal:  Science       Date:  1986-06-20       Impact factor: 47.728

5.  Neutralizing antibodies to visna lentivirus: mechanism of action and possible role in virus persistence.

Authors:  S Kennedy-Stoskopf; O Narayan
Journal:  J Virol       Date:  1986-07       Impact factor: 5.103

6.  Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS.

Authors:  H J Alter; J W Eichberg; H Masur; W C Saxinger; R Gallo; A M Macher; H C Lane; A S Fauci
Journal:  Science       Date:  1984-11-02       Impact factor: 47.728

7.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

8.  Infection of chimpanzees by human T-lymphotropic retroviruses in brain and other tissues from AIDS patients.

Authors:  D C Gajdusek; H L Amyx; C J Gibbs; D M Asher; P Rodgers-Johnson; L G Epstein; P S Sarin; R C Gallo; A Maluish; L O Arthur
Journal:  Lancet       Date:  1985-01-05       Impact factor: 79.321

9.  Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection.

Authors:  J Goudsmit; F de Wolf; D A Paul; L G Epstein; J M Lange; W J Krone; H Speelman; E C Wolters; J Van der Noordaa; J M Oleske
Journal:  Lancet       Date:  1986-07-26       Impact factor: 79.321

10.  Type-restricted neutralization of molecular clones of human immunodeficiency virus.

Authors:  D J Looney; A G Fisher; S D Putney; J R Rusche; R R Redfield; D S Burke; R C Gallo; F Wong-Staal
Journal:  Science       Date:  1988-07-15       Impact factor: 47.728

View more
  83 in total

1.  Neutralization profiles of sera from human immunodeficiency virus (HIV)-infected individuals: relationship to HIV viral load and CD4 cell count.

Authors:  M Nokta; P Turk; K Loesch; R B Pollard
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

2.  Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees.

Authors:  T Beaumont; S Broersen; A van Nuenen; H G Huisman; A M de Roda Husman; J L Heeney; H Schuitemaker
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.

Authors:  R Q Warren; S A Anderson; W M Nkya; J F Shao; C W Hendrix; G P Melcher; R R Redfield; R C Kennedy
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

4.  Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys.

Authors:  D P Burns; R C Desrosiers
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

5.  Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.

Authors:  C Y Kang; P Nara; S Chamat; V Caralli; T Ryskamp; N Haigwood; R Newman; H Köhler
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

6.  Cross-reactive T-cell proliferative responses to V3 peptides corresponding to different geographical HIV-1 isolates in HIV-seropositive individuals.

Authors:  P N Nehete; P C Johnson; S J Schapiro; R B Arlinghaus; K J Sastry
Journal:  J Clin Immunol       Date:  1996-03       Impact factor: 8.317

Review 7.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

8.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

Authors:  M Thali; J P Moore; C Furman; M Charles; D D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

9.  Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum.

Authors:  M Schreiber; H Petersen; C Wachsmuth; H Müller; F T Hufert; H Schmitz
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

10.  High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.

Authors:  Katie L Davis; Elin S Gray; Penny L Moore; Julie M Decker; Aidy Salomon; David C Montefiori; Barney S Graham; Michael C Keefer; Abraham Pinter; Lynn Morris; Beatrice H Hahn; George M Shaw
Journal:  Virology       Date:  2009-03-18       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.